GNOM
Global X Genomics & Biotechnology ETF
Set alert
- YTD
- +53.12%
- 1 year
- +56.57%
- Open
- 71.04
- Prev close
- 72.39
- Mkt cap
- 114.96M
- Vol
- 24.66K
- Avg vol
- 33.96K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 68.66
- High
- 71.30
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.52
- 200-d avg
- 10.79
News
1 month ago benzinga.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
2 months ago defenseworld.net
Bank of America Corp DE Boosts Stake in Global X Genomics & Biotechnology ETF $GNOM
Bank of America Corp DE raised its stake in shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM) by 67.8% during the undefined quarter, according to its most recent filing with the…
2 months ago defenseworld.net
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?
Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of…
3 months ago 247wallst.com
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
7 months ago zacks.com
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
9 months ago defenseworld.net
Comprehensive Money Management Services LLC Reduces Position in Global X Genomics & Biotechnology ETF $GNOM
Comprehensive Money Management Services LLC decreased its position in shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM) by 74.4% during the undefined quarter, according to the company…
9 months ago defenseworld.net
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200-Day Moving Average – Should You Sell?
Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of…
11 months ago defenseworld.net
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200-Day Moving Average – Here’s Why
Shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $37.63…
1 year ago benzinga.com
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.
1 year ago zacks.com
Best-Performing ETF Areas of Last Week
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
2 years ago investorplace.com
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier…
2 years ago investorplace.com
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
2 years ago investorplace.com
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
2 years ago seekingalpha.com
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment
GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying…
2 years ago investorplace.com
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
2 years ago investorplace.com
3 Gene Editing Stocks With Unprecedented Surge Potential
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent…
2 years ago investorplace.com
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2 years ago etftrends.com
VettaFi Voices On: The Outlook for 2024
Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for…
3 years ago investorplace.com
3 Gene Editing Stocks to Generate Super-Charged Gains
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,…
3 years ago seekingalpha.com
Healthcare Dashboard For August And Focus On GNOM
This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value…
3 years ago seekingalpha.com
GNOM: A Genomics ETF That Will Have Its Day, Even If Not Right Now
GNOM is a $200 million ETF that invests in a forward-looking set of innovative businesses focused on the genomics industry. This is a long-term growth area, but it will need to get more profitable to…
3 years ago investorplace.com
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the…
-
5 years ago benzinga.com
68 Stocks Trading Near 52-Week Highs Just After Open On Thursday, Nov. 5, 2020:
Full List: EYE, FIVN, BLDR, HUBS, GO, SNPS, NTLA, PCTY, TTEC, REZI, SI, GRBK, CARR, DRIV, IPHI, MELI, CDNS, TA, TMO, GNOM, HERO, DNKN, GNRC, CAF, QCLN, SFTTW, DVA, CROX, MCHI, MGNI, IIPR, BEEM, LRCX,…